INTERNATIONAL JOURNAL OF PHARMACY AND BIOLOGICAL SCIENCE (IJPBS)
Published April 1, 2026 | Version v1
Journal article Open

Review And Analysis of Essential Protein Targets of Mycobacterium leprae for Novel Anti-leprosy Drug Development

Authors/Creators

  • 1. 1G. H. Raisoni Institute of Life Sciences, Shradha Park, B-37/39, Wadi Link Road, Hingna, Nagpur, Maharashtra 440016

Description

Abstract
Leprosy, caused by Mycobacterium leprae, remains a significant public health concern in several parts of the world in spite of the availability of multidrug therapy. The emergence of drug resistance and the prolonged duration of treatment highlight the urgent need for novel therapeutic strategies. Due to its highly reduced genome and obligate intracellular lifestyle, M. leprae relies on a limited set of essential proteins for survival, persistence, and pathogenicity, making these proteins attractive targets for drug discovery. This review provides a comprehensive analysis of key essential protein targets involved in critical biological processes such as cell wall biosynthesis, energy metabolism, DNA replication, transcription, translation, and stress response mechanisms. Particular emphasis is placed on enzymes and regulatory proteins that are indispensable for bacterial viability and show minimal homology with human proteins, thereby reducing the risk of host toxicity. By integrating current knowledge from genomics, proteomics, and computational drug discovery studies, this review highlights promising targets that could facilitate the development of selective and effective antileprosy agents. The identification and validation of these essential proteins may accelerate the design of novel therapeutics and contribute to improved management and eventual eradication of leprosy.

Keywords 
Leprosy, Mycobacterium leprae, Multidrug Therapy, Proteins

Files

47-55-Sumbul Fatma Khan-6912500132.pdf

Files (587.7 kB)

Name Size Download all
md5:de2eaa23857903ce7a4ef3e05e029463
587.7 kB Preview Download

Additional details

References

  • 1. Santacroce L, Prete R Del, Charitos IA, Bottalico L. Mycobacterium leprae: A historical study on the origins of leprosy and its social stigma. Infez Med. 2021;29(4):623. doi:10.53854/LIIM-2904-18 2. Talhari C, Talhari S, Penna GO. Clinical aspects of leprosy. Clin Dermatol. 2015;33(1):26-37. doi: 10.1016/j.clindermatol.2014.07.002 3. Sugawara-Mikami M, Tanigawa K, Kawashima A, et al. Pathogenicity and virulence of Mycobacterium leprae. Virulence. 2022;13(1):1985-2011. doi:10.1080/21505594.2022.2141987. 4. Bhamidi S, Scherman MS, Jones V, et al. Detailed structural and quantitative analysis reveals the spatial organization of the cell walls of in vivo grown Mycobacterium leprae and in vitro grown Mycobacterium tuberculosis. Journal of Biological Chemistry. 2011;286(26):23168-23177. doi:10.1074/jbc.M110.210534 5. Cabral N, de Figueiredo V, Gandini M, et al. Modulation of the Response to Mycobacterium leprae and Pathogenesis of Leprosy. Front Microbiol. 2022; 13:918009. doi:10.3389/FMICB.2022.918009/FULL 6. Rehna EA, Munavar H, Dharmalingam K, Shakila M, Natesan S. Mycobacterium leprae hsp18 promoter-EGFP transcriptional fusion construct: Environmental stress and strain-specific expression. Gene. 2023; 851:147034. doi: 10.1016/J.GENE.2022.147034 7. Deps PD, Nasser S, Guerra P, Simon M, Birshner RDC, Rodrigues LC. Adverse effects from multi-drug therapy in leprosy: A Brazilian study. Lepr Rev. 2007;78(3):216-222. doi:10.47276/LR.78.3.216 8. Li X, Li G, Yang J, et al. Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2022;23(20). doi:10.3390/IJMS232012443/S1 9. Job C, Jayakumar J, MKTA journal of, 2008 undefined. Transmission of leprosy: a study of skin and nasal secretions of household contacts of leprosy patients using PCR. europepmc.org. Accessed January 20, 2026. https://europepmc.org/article/med/18337353 10. Sugawara-Mikami M, Tanigawa K, Kawashima A, et al. Pathogenicity and virulence of Mycobacterium leprae. Virulence. 2022;13(1):1985-2011. doi:10.1080/21505594.2022.2141987 11. Palit A, dermatology HKI journal of, and venereology, 2020 undefined. Prevention of transmission of leprosy: the current scenario. ijdvl.com. Published online 2020. doi:10.4103/ijdvl.IJDVL_326_19 12. Shyam M, Kumar S, Singh V. Unlocking Opportunities for Mycobacterium leprae and Mycobacterium ulcerans. ACS Infect Dis. 2024;10(2):251-269. doi:10.1021/ACSINFECDIS.3C00371 13. Acebrón-García-de-Eulate M, Blundell TL, Vedithi SC. Strategies for drug target identification in Mycobacterium leprae. Drug Discov Today. 2021;26(7):1569-1573. doi:10.1016/J.DRUDIS.2021.03.026 14. Tabouret G, Astarie-Dequeker C, Demangel C, et al. Mycobacterium leprae Phenolglycolipid-1 Expressed by Engineered M. bovis BCG Modulates Early Interaction with Human Phagocytes. PLoS Pathog. 2010;6(10): e1001159. doi:10.1371/JOURNAL.PPAT.1001159 15. Spencer J, review PBL, 2011 undefined. The Role of Mycobacterium leprae Phenolic Glycolipid I (PGL-I) in Serodiagnosis and in the Pathogenesis of Leprosy. leprosyreview.org. Accessed January 20, 2026. https://leprosyreview.org/article/82/4/34-4357 16. Chan J, Fan X, Hunter SW, Brennan PJ, Bloom BR. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun. 1991;59(5):1755-1761. doi:10.1128/IAI.59.5.1755-1761.1991;CTYPE:STRING:JOURNAL 17. Chatterjee D, Glycobiology KK, 1998 undefined. Mycobacterial lipoarabinomannan: an extraordinary lipoheteroglycan with profound physiological effects. academic.oup.com. Accessed January 20, 2026. https://academic.oup.com/glycob/article-abstract/8/2/113/830595 18. Bahia El Idrissi N, Das PK, Fluiter K, et al. M. leprae components induce nerve damage by complement activation: identification of lipoarabinomannan as the dominant complement activator. Springer. 2015;129(5):653-667. doi:10.1007/S00401-015-1404-5 19. Williams DL, Pittman TL, Deshotel M, Oby-Robinson S, Smith I, Husson R. Molecular basis of the defective heat stress response in Mycobacterium leprae. J Bacteriol. 2007;189(24):8818-8827. doi:10.1128/JB.00601-07;JOURNAL:JOURNAL:JB;WGROUP:STRING:PUBLICATION 20. Bajaj D, … JBTD the SL of, 2012 undefined. Heat shock proteins in Mycobacterium tuberculosis: involvement in survival and virulence of the pathogen. books.google.com. Accessed January 20, 2026. 21. Nandi SK, Chakraborty A, Panda AK, et al. Interaction of ATP with a Small Heat Shock Protein from Mycobacterium leprae: Effect on Its Structure and Function. journals.plos.org. 2015;9(3):3661. doi: 10.1371/JOURNAL.PNTD.0003661 22. Das M, David D, Horo I, et al. Mycobacterium leprae and host immune transcriptomic signatures for reactional states in leprosy. frontiersin.org. 2023;14. doi:10.3389/FMICB.2023.1113318/FULL 23. Reece ST, Ireton G, Mohamath R, et al. ML0405 and ML2331 Are Antigens of Mycobacterium leprae with Potential for Diagnosis of Leprosy. journals.asm.org. 2006;13(3):333-340. doi:10.1128/CVI.13.3.333-340.2006 24. Geluk A, Van Meijgaarden KE, Franken KLMC, et al. Identification and characterization of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosis. Infect Immun. 2002;70(5):2544-2548. doi:10.1128/IAI.70.5.2544-2548.2002; WGROUP: STRING: PUBLICATION 25. Gey van Pittius NC, Warren RM, Van Heiden PD, et al. ESAT-6 and CFP-10: what is the diagnosis? journals.asm.org. 2002;70(11):6509-6511. doi:10.1128/IAI.70.11.6509-6511.2002 26. Parkash O, Pandey R, AKL in applied, 2007 undefined. Performance of recombinant ESAT‐6 antigen (ML0049) for detection of leprosy patients. academic.oup.com. Accessed January 20, 2026. https://academic.oup.com/lambio/article-abstract/44/5/524/6703236 27. Malakar B, Chauhan K, Sanyal P, et al. Phosphorylation of CFP10 modulates Mycobacterium tuberculosis virulence. mBio. 2023;14(5). doi:10.1128/MBIO.01232-23; WGROUP: STRING: PUBLICATION 28. Geluk A, Van Meijgaarden KE, Franken KLMC, et al. Immunological Crossreactivity of the Mycobacterium leprae CFP‐10 with its Homologue in Mycobacterium tuberculosis. Wiley Online Library. 2004;59(1):66-70. doi:10.1111/J.0300-9475.2004. 01358.X 29. Parkash O, Kumar A, Nigam A, Girdhar BK. Detection of antibodies against Mycobacterium leprae culture filtrate protein-10 in leprosy patients. microbiologyresearch.org. 2006;55(10):1337-1341. doi:10.1099/JMM.0.46587-0 30. Ohyama H, Matsushita S, Nishimura F, et al. T cell responses to major membrane protein II (MMP II) of Mycobacterium leprae are restricted by HLA-DR molecules in patients with leprosy. Vaccine. 2001;20(3-4):475-482. doi:10.1016/S0264-410X(01)00354-1 31. Sauer M, Salomão H, … GRC in, 2015 undefined. Genetics of leprosy: expected and unexpected developments and perspectives. Elsevier. Accessed January 20, 2026. https://www.sciencedirect.com/science/article/pii/S0738081X14002296 32. Vardhini D, Suneetha S, Ahmed N, Infection DJ, and G, 2004 undefined. Comparative proteomics of the Mycobacterium leprae binding protein myelin P0: its implication in leprosy and other neurodegenerative diseases. Elsevier. Accessed January 20, 2026. https://www.sciencedirect.com/science/article/pii/S1567134803001242 33. Guragain S, Upadhayay N, Bhattarai BM. Adverse reactions in leprosy patients who underwent dapsone multidrug therapy: a retrospective study. Taylor & Francis. 2017; 9:73-78. doi:10.2147/CPAA.S135846 34. Raju M, Elkana M, Failbus P, … JPIJ, 2015 undefined. Correlates of defaulting from MDT among leprosy patients. researchgate.net. Accessed January 20, 2026. https://www.researchgate.net/profile/Moturu-Raju/publication/334760950_Original_Article_Correlates_of_Defaulting_from_MDT_among_Leprosy_Patients/links/5d3fe0504585153e592d09ec/Original-Article-Correlates-of-Defaulting-from-MDT-among-Leprosy-Patients.pdf 35. Jindal R, Singh I, Goyal D, et al. Resistance to anti-leprosy drugs in multi-bacillary leprosy patients: The need for transformative action. Indian J Dermatol Venereol Leprol. 2026;92(1):37-42. doi:10.25259/IJDVL_1842_2024 36. Cambau E, Saunderson P, Matsuoka M, et al. antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15. Clinical Microbiology and Infection. 2018;24(12):1305-1310. doi: 10.1016/j.cmi.2018.02.022 37. Pescarini JM, Strina A, Nery JS, et al. Socioeconomic risk markers of leprosy in high-burden countries: A systematic review and meta-analysis. journals.plos.org. 2018;12(7). doi: 10.1371/JOURNAL.PNTD.0006622 38. Deps PD, Nasser S, Guerra P, et al. Adverse effects from multi-drug therapy in leprosy: a Brazilian study. researchonline.lshtm.ac.uk. Accessed January 20, 2026. https://researchonline.lshtm.ac.uk/id/eprint/8604 39. Ebenezer GJ, Pena MT, Daniel AS, et al. Mycobacterium leprae induces Schwann cell proliferation and migration in a denervated milieu following intracutaneous excision axotomy in nine-banded armadillos. Exp Neurol. 2022;352:114053. doi:10.1016/J.EXPNEUROL.2022.114053 40. Bhat R, on CPI perspectives, 2012 undefined. Leprosy: an overview of pathophysiology. Wiley Online Library. 2012;2012. doi:10.1155/2012/181089 41. Mehta H, Jain S, Narang T, … SCIJ of, 2025 undefined. Leprosy reactions: new knowledge on pathophysiology, diagnosis, treatment and prevention. ijdvl.com. Published online 2024. doi:10.25259/IJDVL_915_2024 42. Pinheiro RO, Rosa PS, Spencer JS, Soares CT. Leprosy reactions: new knowledge on pathophysiology, diagnosis, treatment and prevention. frontiersin.org. 2022;9. doi:10.3389/FMED.2022.1072274/FULL 43. Gao Y, Liu J, Li Q, Medical ZZER for, 2021 undefined. Clinical and pathological features of different types of leprosy. europeanreview.org. Accessed January 20, 2026. https://www.europeanreview.org/wp/wp-content/uploads/1050-1059.pdf?utm_medium=email&utm_source=transaction 44. Bhat RM, Prakash C. Leprosy: An Overview of Pathophysiology. Interdiscip Perspect Infect Dis. 2012;2012(1):181089. doi:10.1155/2012/181089 45. Hilder R, Review DLL, 2020 undefined. The adverse drug effects of dapsone therapy in leprosy: a systematic review. leprosyreview.org. Accessed January 20, 2026. https://leprosyreview.org/article/91/3/20-20304 46. Nery J, Ramond A, Pescarini J, AATLG, 2019 undefined. Socioeconomic determinants of leprosy new case detection in the 100 million Brazilian Cohort: a population-based linkage study. thelancet.com. Accessed January 20, 2026. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30260-8/fulltext 47. Cambau E, Saunderson P, Matsuoka M, et al. antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15. Clinical Microbiology and Infection. 2018;24(12):1305-1310. doi: 10.1016/j.cmi.2018.02.022